Free PANCE Practice Questions

Pulmonary PANCE practice questions

10 free, board-style Pulmonary questions for the PANCE, each with the correct answer and a complete explanation. No email, no account required.

Pulmonary is 9% of the PANCE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1PulmonaryMedium
A 45-year-old man with chronic obstructive pulmonary disease (COPD) reports two exacerbations in the past year, one of which required an emergency visit. He uses a short-acting bronchodilator only as needed but remains symptomatic with exertional dyspnea, and he continues to smoke. Post-bronchodilator spirometry shows an FEV1 of 55% predicted, and the blood eosinophil count is 120 cells/uL. Which of the following inhaler regimens is the most appropriate initial maintenance therapy?
  • ALABA monotherapy
  • BLAMA + LABA + ICS
  • CICS monotherapy
  • DLAMA + LABA
  • ELAMA monotherapy
Reveal answer & full explanation
Correct answer: D — LAMA + LABA
  • ALABA monotherapy
  • BLAMA + LABA + ICS
  • CICS monotherapy
  • DLAMA + LABA✓
  • ELAMA monotherapy

Why LAMA + LABA is correct

  • This patient meets GOLD Group E criteria (two exacerbations in the past year, including one requiring an emergency visit), which defines high future-exacerbation risk
  • Per current GOLD guidance, the preferred initial maintenance therapy for Group E is dual long-acting bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting beta-agonist (LABA)
  • A blood eosinophil count below 300 cells/uL argues against starting an inhaled corticosteroid (ICS), which is added mainly when eosinophils are 300 cells/uL or higher or when exacerbations persist on dual bronchodilators with eosinophils of 100 cells/uL or higher

Why the others are wrong

  • LAMA + LABA + ICS — triple therapy is an escalation step (or initial therapy only when eosinophils are at least 300 cells/uL); with eosinophils of 120 cells/uL it is not the appropriate starting regimen (right-diagnosis-wrong-step)
  • LAMA monotherapy — a single long-acting bronchodilator is maintenance therapy, but GOLD favors dual LAMA plus LABA over either agent by itself in Group E because the combination produces greater symptom relief and fewer exacerbations (right-category-wrong-intensity)
  • ICS monotherapy — an inhaled corticosteroid without a bronchodilator backbone is not recommended at any stage of COPD and increases pneumonia risk (confused with first-line asthma management)
  • LABA monotherapy — stepping up from an as-needed short-acting bronchodilator to a long-acting beta-agonist seems natural, and unlike in asthma a LABA without an ICS is acceptable in COPD, but with two exacerbations in the past year he is in Group E, where GOLD recommends starting dual LAMA plus LABA; even as single-agent therapy, a LAMA reduces exacerbations more than a LABA (anchoring on his rescue drug class)
Question 2PulmonaryMedium
A 28-year-old woman with asthma reports symptoms every day and nighttime awakenings about three times per week. She uses her short-acting beta-agonist daily for relief, and her symptoms limit some normal activities. She is currently taking no controller medication. Spirometry shows an FEV1 of 72% predicted. Using the National Asthma Education and Prevention Program (NAEPP) framework, which of the following is the most appropriate initial treatment step?
  • AStep 2
  • BStep 3
  • CStep 4
  • DStep 1
  • EStep 5
Reveal answer & full explanation
Correct answer: B — Step 3
  • AStep 2
  • BStep 3✓
  • CStep 4
  • DStep 1
  • EStep 5

Why Step 3 is correct

  • Daily symptoms, nighttime awakenings more than once weekly, and an FEV1 of 60-80% predicted classify this as moderate persistent asthma
  • Per the NAEPP framework, moderate persistent asthma in an adolescent or adult is initiated at Step 3: low-dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA), or low-dose ICS-formoterol used as both controller and reliever
  • Control is reassessed in a few weeks and therapy is stepped up if it is not achieved

Why the others are wrong

  • Step 1 — Step 1 is for intermittent asthma (symptoms two days per week or fewer, rare nighttime awakenings); daily symptoms exclude it (premature closure on the mildest category)
  • Step 2 — Step 2 corresponds to mild persistent asthma; daily symptoms and nighttime awakenings more than once weekly exceed mild criteria (buzzword-matching "persistent" without grading its severity)
  • Step 4 — Step 4 is reserved for severe persistent disease (symptoms throughout the day, awakenings often nightly, FEV1 under 60%); the FEV1 of 72% and three-nights-per-week awakenings defeat it (anchoring on the daily symptoms while ignoring the lung function)
  • Step 5 — a high-intensity step used for severe persistent asthma (where initial therapy is Step 4 or 5) or for asthma not controlled at Step 4; an FEV1 of 72% and awakenings three nights per week meet moderate, not severe, criteria (overestimating severity from daily rescue inhaler use)
Question 3PulmonaryMedium
A 50-year-old man with a 40 pack-year smoking history is found to have a solitary 7-mm solid pulmonary nodule on a CT scan obtained for an unrelated reason. He has no symptoms and no prior imaging available for comparison. There is no associated lymphadenopathy, and the remainder of the chest CT is normal. According to the Fleischner Society guidelines for incidental solid pulmonary nodules, which of the following is the most appropriate next step?
  • APET-CT of the chest within one month
  • BA single follow-up CT at 12 months
  • CFollow-up chest CT at 3 months
  • DCT at 6-12 months, then 18-24 months
  • ENo additional surveillance imaging
Reveal answer & full explanation
Correct answer: D — CT at 6-12 months, then 18-24 months
  • APET-CT of the chest within one month
  • BA single follow-up CT at 12 months
  • CFollow-up chest CT at 3 months
  • DCT at 6-12 months, then 18-24 months✓
  • ENo additional surveillance imaging

Why CT at 6-12 months, then 18-24 months is correct

  • For a solid, solitary nodule measuring 6-8 mm in a high-risk patient (heavy smoker), the Fleischner Society recommends an initial follow-up CT at 6-12 months and, if stable, a second CT at 18-24 months
  • Two stable time points are required to confirm the nodule is not growing, because a malignant nodule can have a long volume-doubling time
  • A 6-8 mm size with no suspicious features falls below the threshold for immediate tissue characterization

Why the others are wrong

  • No additional surveillance imaging — omitting follow-up applies only to nodules under 6 mm; a 7-mm nodule in a high-risk patient must be tracked (undertreatment, premature closure)
  • PET-CT of the chest within one month — PET-CT or tissue sampling is reserved for solid nodules larger than 8 mm or nodules that grow, and PET has poor sensitivity for sub-centimeter lesions (overtesting, anchoring on cancer fear)
  • A single follow-up CT at 12 months — one scan cannot establish two-year stability; the guideline requires a second interval scan, so a single follow-up risks missing slow growth (confused with the optional single 12-month CT Fleischner reserves for high-risk nodules under 6 mm)
  • Follow-up chest CT at 3 months — a short-interval CT at about 3 months is one of the options Fleischner offers for solid nodules larger than 8 mm; for a 6-8 mm nodule the first follow-up is at 6-12 months, and a single early scan cannot establish two-year stability (confusing the 6-8 mm and over-8 mm size thresholds)
Question 4PulmonaryMedium
A 40-year-old woman who has never smoked reports several months of progressive exertional dyspnea. She also describes proximal muscle weakness and cracked, fissured skin over the lateral aspects of the fingers. CT of the chest shows bilateral lower-lobe ground-glass opacities consistent with interstitial lung disease. Serologic testing is positive for anti-Jo-1 antibody. Which of the following is the most likely diagnosis?
  • AIdiopathic pulmonary fibrosis
  • BSystemic sclerosis
  • CHypersensitivity pneumonitis
  • DSarcoidosis
  • EAntisynthetase syndrome
Reveal answer & full explanation
Correct answer: E — Antisynthetase syndrome
  • AIdiopathic pulmonary fibrosis
  • BSystemic sclerosis
  • CHypersensitivity pneumonitis
  • DSarcoidosis
  • EAntisynthetase syndrome✓

Why antisynthetase syndrome is correct

  • Antisynthetase syndrome is defined by an anti-aminoacyl-tRNA synthetase antibody (most commonly anti-Jo-1) combined with interstitial lung disease and inflammatory myopathy
  • The supportive features here complete the classic cluster: mechanic's hands (fissured skin of the lateral fingers), proximal muscle weakness, and bilateral ground-glass interstitial lung disease
  • Anti-Jo-1 positivity with myositis and interstitial lung disease is essentially specific for this syndrome and drives treatment with corticosteroids plus a steroid-sparing agent such as mycophenolate or azathioprine

Why the others are wrong

  • Idiopathic pulmonary fibrosis — IPF is a diagnosis of exclusion in older adults showing a usual interstitial pneumonia (honeycombing) pattern with no autoantibodies or myopathy; the anti-Jo-1 antibody and muscle weakness exclude it (anchoring on interstitial lung disease)
  • Hypersensitivity pneumonitis — this requires an inciting antigen exposure and does not produce anti-Jo-1 antibody, mechanic's hands, or myositis (buzzword-matching on ground-glass opacities)
  • Sarcoidosis — sarcoidosis typically causes bilateral hilar adenopathy with non-caseating granulomas, not anti-Jo-1-associated myositis with mechanic's hands (confused with another interstitial lung disease)
  • Systemic sclerosis — systemic sclerosis also causes lower-lobe ground-glass interstitial lung disease in middle-aged women and involves the fingers, but its skin finding is sclerodactyly with Raynaud phenomenon and its ILD-associated antibody is anti-Scl-70 (anti-topoisomerase I); anti-Jo-1 with mechanic's hands and proximal weakness defines antisynthetase syndrome instead (confused with another connective tissue disease-ILD)
Question 5PulmonaryMedium
A 58-year-old man with a 40-pack-year smoking history and chronic obstructive pulmonary disease reports several weeks of drenching night sweats, a 20-lb unintentional weight loss, and blood-streaked sputum. Chest imaging shows a new 2-cm cavitary lesion in the right upper lobe. He is hemodynamically stable and afebrile in the clinic. Which of the following is the most appropriate next step in management?
  • AInterferon-gamma release assay
  • BCT-guided transthoracic lung biopsy
  • CAFB sputum smear and culture × 3
  • DEmpiric antibiotics for pneumonia
  • EEmpiric systemic antifungal therapy
Reveal answer & full explanation
Correct answer: C — AFB sputum smear and culture × 3
  • AInterferon-gamma release assay
  • BCT-guided transthoracic lung biopsy
  • CAFB sputum smear and culture × 3✓
  • DEmpiric antibiotics for pneumonia
  • EEmpiric systemic antifungal therapy

Why AFB sputum smear and culture × 3 is correct

  • A cavitary right-upper-lobe lesion with night sweats, weight loss, and hemoptysis is the classic presentation of reactivation pulmonary tuberculosis, which must be excluded before anything else.
  • The first step is to collect acid-fast bacilli (AFB) sputum smears and cultures (three specimens) and place the patient in airborne isolation to protect staff and other patients.
  • Smear plus culture, with nucleic acid amplification testing, establishes the diagnosis and drug susceptibility; it is non-invasive, inexpensive, and carries immediate public-health implications.

Why the others are wrong

  • Empiric antibiotics for pneumonia — a subacute cavitary lesion with weeks of constitutional symptoms is not acute bacterial pneumonia; premature closure on the most common cause of a lung infiltrate that also delays TB isolation.
  • CT-guided transthoracic lung biopsy — although malignancy is on the differential in a smoker, an invasive biopsy before active TB is excluded risks aerosolizing organisms and exposing staff; it is a later step, a right-concern-wrong-sequence error.
  • Empiric systemic antifungal therapy — there is no host risk factor or exposure history pointing to an endemic or invasive fungal infection; it buzzword-matches 'cavitary lesion' without justification.
  • Interferon-gamma release assay — a quick TB blood test is tempting, but an IGRA measures immune sensitization rather than active disease, cannot distinguish latent from active infection, and can be negative in active pulmonary TB; a cavitary lesion with constitutional symptoms needs sputum AFB smear, culture, and nucleic acid amplification testing under airborne isolation, a wrong-test-for-the-question error.
Question 6PulmonaryMedium
A 28-year-old man has a second episode of right-sided primary spontaneous pneumothorax. After successful chest tube drainage, which of the following is most appropriate to prevent recurrence?
  • AContralateral prophylactic pleurodesis
  • BProlonged chest tube drainage
  • CVATS with pleurodesis
  • DObservation alone
  • EEndobronchial valve placement
Reveal answer & full explanation
Correct answer: C — VATS with pleurodesis
  • AContralateral prophylactic pleurodesis
  • BProlonged chest tube drainage
  • CVATS with pleurodesis✓
  • DObservation alone
  • EEndobronchial valve placement

Why VATS with pleurodesis is correct

  • After a second ipsilateral primary spontaneous pneumothorax, recurrence risk is 50–80%, so definitive intervention is offered.
  • Video-assisted thoracoscopic surgery (VATS) with mechanical pleurodesis or pleurectomy is the gold standard, with recurrence <5%.
  • Chemical pleurodesis (talc) is an alternative when surgery is not feasible.

Why the others are wrong

  • Prolonged chest tube drainage — evacuates air and seals the current leak but creates no pleural symphysis, so the recurrence risk after a second ipsilateral episode is unchanged
  • Contralateral prophylactic pleurodesis — recurrence prevention is directed at the affected ipsilateral side; treating the unaffected lung is not standard
  • Observation alone — appropriate after a first small primary pneumothorax, but a second ipsilateral event carries a 50-80% recurrence risk and warrants definitive intervention
  • Endobronchial valve placement — one-way endobronchial valves can seal a persistent air leak in patients who are poor surgical candidates, usually with secondary pneumothorax or emphysema, but this young man's leak has already closed, and valves create no pleural symphysis, so they do not lower the recurrence risk after a second ipsilateral episode
Question 7PulmonaryMedium
A 35-year-old man with HIV infection and a CD4 count of 65 cells/µL presents with one week of fever, progressive exertional dyspnea, and a nonproductive cough. He is on no prophylaxis, and his oxygen saturation falls with ambulation. Chest radiograph shows bilateral perihilar interstitial infiltrates, and serum lactate dehydrogenase (LDH) is markedly elevated. Which of the following is the most appropriate treatment?
  • ATrimethoprim-sulfamethoxazole
  • BCeftriaxone plus azithromycin
  • CValganciclovir hydrochloride
  • DAzithromycin and ethambutol
  • EAmphotericin B and flucytosine
Reveal answer & full explanation
Correct answer: A — Trimethoprim-sulfamethoxazole
  • ATrimethoprim-sulfamethoxazole✓
  • BCeftriaxone plus azithromycin
  • CValganciclovir hydrochloride
  • DAzithromycin and ethambutol
  • EAmphotericin B and flucytosine

Why Trimethoprim-sulfamethoxazole is correct

  • Advanced HIV (CD4 <200 cells/µL), subacute fever and nonproductive cough, exertional desaturation, bilateral perihilar/interstitial infiltrates, and a markedly elevated LDH are the classic picture of Pneumocystis jirovecii pneumonia (PCP).
  • High-dose trimethoprim-sulfamethoxazole (TMP-SMX) for 21 days is first-line therapy.
  • Adjunctive corticosteroids are added when room-air PaO₂ is <70 mmHg or the A-a gradient is ≥35 mmHg.

Why the others are wrong

  • Azithromycin and ethambutol — Part of a Mycobacterium avium complex regimen, which in AIDS presents as disseminated disease (weight loss, cytopenias, hepatosplenomegaly) rather than this interstitial pneumonitis; a buzzword trap for 'HIV plus cough.'
  • Ceftriaxone plus azithromycin — Empiric coverage for typical and atypical community-acquired pneumonia, which causes focal lobar consolidation and a productive cough rather than the diffuse interstitial pattern and high LDH seen here; a premature-closure trap.
  • Valganciclovir hydrochloride — Treats CMV disease, which in AIDS usually presents as retinitis or colitis rather than this LDH-driven interstitial pneumonitis; an anchoring trap on 'opportunistic infection.'
  • Amphotericin B and flucytosine — Pneumocystis jirovecii is classified as a fungus, so an antifungal regimen seems logical, but its cell membrane contains cholesterol rather than ergosterol, so amphotericin and the azoles are ineffective against it; amphotericin B plus flucytosine is induction therapy for cryptococcal meningitis, which presents with subacute headache and fever rather than this interstitial pneumonitis with a markedly elevated LDH; a classification trap on 'Pneumocystis is a fungus.'
Question 8PulmonaryMedium
A previously healthy 50-year-old man presents with three days of fever, productive cough, and pleuritic chest pain. He has no comorbidities and is well enough for outpatient management. Examination and chest radiograph reveal right lower lobe consolidation, and a sputum Gram stain shows gram-positive diplococci. Which of the following is the most appropriate outpatient antibiotic?
  • ATrimethoprim-sulfamethoxazole (TMP-SMX)
  • BAzithromycin
  • CCiprofloxacin
  • DCephalexin
  • EAmoxicillin
Reveal answer & full explanation
Correct answer: E — Amoxicillin
  • ATrimethoprim-sulfamethoxazole (TMP-SMX)
  • BAzithromycin
  • CCiprofloxacin
  • DCephalexin
  • EAmoxicillin✓

Why Amoxicillin is correct

  • Gram-positive diplococci with lobar consolidation identify Streptococcus pneumoniae.
  • For a healthy outpatient with community-acquired pneumonia and no comorbidities, current IDSA/ATS guidance lists high-dose amoxicillin (or doxycycline) as preferred first-line therapy; a beta-lactam is the most reliable agent against documented pneumococcus.
  • Amoxicillin provides direct, high-level coverage of S. pneumoniae with a favorable safety and resistance profile.

Why the others are wrong

  • Azithromycin — Macrolide monotherapy is recommended only where local pneumococcal resistance is <25%, and U.S. resistance now exceeds that, so it is not preferred for documented pneumococcus; a buzzword-matching trap for 'CAP equals azithromycin.'
  • Trimethoprim-sulfamethoxazole (TMP-SMX) — Unreliable against S. pneumoniae and not a recommended CAP regimen; a wrong-spectrum trap.
  • Cephalexin — A first-generation cephalosporin with unreliable activity against penicillin-nonsusceptible S. pneumoniae and no place in current CAP guidance, which relies on the high serum exposure of high-dose amoxicillin; a wrong-beta-lactam trap.
  • Ciprofloxacin — A fluoroquinolone, which makes it look like a pneumonia drug, but ciprofloxacin is not a respiratory fluoroquinolone: its activity against S. pneumoniae is weak and unreliable, and it is not a recommended outpatient CAP regimen; a wrong-fluoroquinolone trap.
Question 9PulmonaryMedium
A 60-year-old man in the ICU develops fever to 38.9 C, leukocytosis, increasing purulent tracheal secretions, and a new right lower lobe infiltrate on chest radiograph 3 days after intubation for respiratory failure. He has no known multidrug-resistant organism risk factors. Empiric therapy is initiated before culture results return. Which of the following antibiotics is most appropriate?
  • ATrimethoprim-sulfamethoxazole
  • BPiperacillin-tazobactam
  • CErtapenem
  • DCeftriaxone
  • EAzithromycin
Reveal answer & full explanation
Correct answer: B — Piperacillin-tazobactam
  • ATrimethoprim-sulfamethoxazole
  • BPiperacillin-tazobactam✓
  • CErtapenem
  • DCeftriaxone
  • EAzithromycin

Why Piperacillin-tazobactam is correct

  • This is ventilator-associated pneumonia (VAP), defined as a new infiltrate with systemic signs of infection arising 48 hours or more after intubation.
  • VAP is frequently caused by drug-resistant gram-negative organisms, most notably Pseudomonas aeruginosa, as well as MRSA and Acinetobacter, so empiric coverage must include an anti-pseudomonal agent.
  • Piperacillin-tazobactam is an anti-pseudomonal beta-lactam and is an appropriate empiric backbone; cefepime or meropenem are alternatives.
  • Because piperacillin-tazobactam does not cover MRSA, empiric vancomycin or linezolid is typically added unless local MRSA prevalence is documented low, with de-escalation once cultures return.

Why the others are wrong

  • Ceftriaxone — Ceftriaxone is a third-generation cephalosporin appropriate for community-acquired pneumonia but lacks reliable anti-pseudomonal activity, making it inadequate for VAP.
  • Trimethoprim-sulfamethoxazole — Trimethoprim-sulfamethoxazole is used for Stenotrophomonas, Pneumocystis, and some MRSA infections but does not cover Pseudomonas empirically.
  • Azithromycin — Azithromycin targets atypical pathogens such as Legionella and Mycoplasma in community-acquired pneumonia and has no role as empiric monotherapy for ventilator-associated pneumonia.
  • Ertapenem — a carbapenem, so it looks broad, and older early-onset VAP schemes allowed it, but unlike meropenem it lacks activity against Pseudomonas aeruginosa and Acinetobacter, and current IDSA/ATS guidance calls for antipseudomonal coverage in every empiric VAP regimen, even without MDR risk factors; a wrong-carbapenem trap.
Question 10PulmonaryMedium
A 65-year-old man who smokes and has chronic obstructive pulmonary disease (COPD) presents with jugular venous distention (JVD), hepatomegaly, bilateral pitting edema, a loud P2, and SpO₂ 86% at rest. Echocardiography shows right ventricular (RV) dilation with normal left ventricular (LV) function. Which of the following is the most likely diagnosis?
  • ARestrictive cardiomyopathy
  • BConstrictive pericarditis
  • CCor pulmonale
  • DCardiac tamponade
  • ERight ventricular infarction
Reveal answer & full explanation
Correct answer: C — Cor pulmonale
  • ARestrictive cardiomyopathy
  • BConstrictive pericarditis
  • CCor pulmonale✓
  • DCardiac tamponade
  • ERight ventricular infarction

Why Cor pulmonale is correct

  • Cor pulmonale is right heart failure caused by pulmonary disease; COPD is the most common cause
  • Mechanism: COPD → hypoxic pulmonary vasoconstriction → pulmonary hypertension → RV failure
  • The right-sided congestion (JVD, hepatomegaly, edema), loud P2, resting hypoxemia, and echo showing RV dilation with preserved LV function fit this diagnosis

Why the others are wrong

  • Right ventricular infarction — an acute RV infarct also gives JVD and a dilated RV, but it presents abruptly with ischemic chest pain and hypotension plus inferior ST elevation, not with chronic hepatomegaly, dependent edema, a loud P2, and resting hypoxemia (confused-with-X)
  • Cardiac tamponade — There is no effusion, pulsus paradoxus, or equalized pressures to suggest tamponade (buzzword-matching 'JVD' without the rest of the triad)
  • Restrictive cardiomyopathy — Restrictive cardiomyopathy impairs filling of both ventricles rather than producing isolated RV dilation with a clear pulmonary cause (confused-with-X)
  • Constrictive pericarditis — constriction also produces JVD, hepatomegaly, and edema, but a rigid pericardium limits filling so the ventricles are not dilated, and it does not explain a loud P2 or resting hypoxemia; echo would typically show a septal bounce with respiratory variation in ventricular filling, often with a thickened pericardium, rather than isolated RV dilation (confused-with-X)

Additional high-yield points

  • Treatment: (1) supplemental O₂ to maintain SpO₂ >90% — long-term oxygen improves survival in COPD with resting hypoxemia; (2) smoking cessation, which also lowers mortality, and optimized COPD therapy; (3) diuretics for volume overload

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANCE question →

Pulmonary PANCE practice: FAQ

Are these Pulmonary PANCE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANCE is Pulmonary?

Pulmonary makes up 9% of the PANCE content blueprint. FirstPassPA's timed PANCE exams are dealt to the same weights, so a practice exam carries the same share of Pulmonary questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Pulmonary questions in the app, or take a full timed PANCE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.